300049.SZ
福瑞医科
SZSE · Healthcare · C 制造业 · CN
CNY 37.95
−8.93%Year over year
Reported trailing growth
- Revenue
- +19.8%
- EBITDA
- —
- EBIT
- +49.8%
- EPS
- +57.9%
- Free cash flow
- +747.3%
- Operating cash flow
- +42.5%
Forward estimates
Based on analyst estimates
- Revenue
- -74.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +16.5%
- EBITDA
- +21.0%
- EBIT
- +24.1%
- Net income
- +16.3%
- EPS
- +15.9%
- Free cash flow
- +18.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026